TFPI (tissue factor pathway inhibitor) is an anticoagulant protein that prevents intravascular coagulation through inhibition of fXa (Factor Xa) and the TF (tissue factor)-fVIIa (Factor VIIa) complex. Localization of TFPI within caveolae enhances its anticoagulant activity. To define further how caveolae contribute to TFPI anticoagulant activity, CHO (Chinese-hamster ovary) cells were co-transfected with TF and membraneassociated TFPI targeted to either caveolae [TFPI-GPI (TFPIglycosylphosphatidylinositol anchor chimaera)] or to bulk plasma membrane [TFPI-TM (TFPI-transmembrane anchor chimaera)]. Stable clones had equal expression of surface TF and TFPI. TX-114 cellular lysis confirmed localization of TFPI-GPI to detergent-insoluble membrane fractions, whereas TFPI-TM localized to the aqueous phase. TFPI-GPI and TFPI-TM were equally effective direct inhibitors of fXa in amidolytic assays.
INTRODUCTION
TFPI (tissue factor pathway inhibitor) is an anticoagulant protein that down-regulates the initial stages of the blood coagulation cascade that is activated when TF (tissue factor) is exposed to flowing blood following either vascular injury or intravascular inflammation. TFPI is a multivalent Kunitz-type serine protease inhibitor mediating its anticoagulant activity by inhibiting fXa (Factor Xa) via its second Kunitz domain and then producing feedback inhibition of the TF-fVIIa (Factor VIIa) complex with the first Kunitz domain [1] . The physiological importance of TFPI may be best demonstrated by the embryonic lethal phenotype of mice lacking functional TFPI, with death caused by unfettered TF procoagulant activity producing an apparent consumptive coagulopathy [2] . TFPI deficiency has not been identified in humans, suggesting that it results in embryonic death in humans as well as in mice.
TFPI is an alternatively spliced protein, with two forms identified in humans [3] [4] [5] . TFPIα is the full-length form. TFPIα associates with endothelium possibly through indirect binding to an, as yet, unidentified GPI (glycosylphosphatidylinositol)-anchored binding protein [6] [7] [8] . In addition, heparin infusion produces a 2-4-fold increase in human plasma TFPIα [9, 10] . This heparin-releasable TFPIα probably associates non-specifically with endothelium glycosaminoglycans. Alternative splicing in the 3 end of the TFPI gene produces TFPIβ, a truncated protein with a C-terminal domain distinct from TFPIα [4] . The C-terminal domain of TFPIβ encodes a GPI-anchor-binding sequence that allows for direct binding to the endothelial surface [11] . TFPIα and TFPIβ both have the first and second Kunitz domains and inhibit TF-fVIIa and fXa activity in a variety of in vitro assays [3, 11, 12] .
The association of TFPI with the cell surface via a GPI anchor results in its localization within lipid raft microdomains on cellular surfaces [7, 8, 11] and suggests that lipid rafts may be important for their biological function. Lipid rafts are detergentinsoluble areas of the cell membrane containing highly ordered glycosphingolipids and cholesterol that disrupt the relatively disordered loosely packed phospholipids that compose the bulkphase cellular membrane. Caveolin-1 binds cholesterol [13] within lipid rafts and produces invaginated pits on the cell surface called caveolae [14] . Like lipid rafts, caveolae are disrupted by the chemical M-β-CD (methyl-β-cyclodextrin), which removes cholesterol from caveolin-1. When cholesterol is removed, caveolae flatten, lack intramembrane proteins and move freely in a lateral direction within the membrane [15] .
Caveolae are abundant on the surface of endothelial cells, the primary cellular source of TFPI, and caveolin-1 expression has been shown to enhance TFPI cell-surface expression and anticoagulant activity [16] . Down-regulation of TF-fVIIa procoagulant activity by TFPI on the cell surface coincides with translocation of the TF-fVIIa complex from the bulk-phase membrane into caveolae. Because caveolae inefficiently support TF-fVIIa activity, it has been hypothesized that the translocation acts to further down-regulate TF-fVIIa procoagulant activity [8] .
A previous study using HEK (human embryonic kidney)-293 cells, which do not express caveolin-1, indicated that lipid rafts do not play a role in the down-regulation of TF activity by TFPI [17] . In order to better understand the role of caveolae in TFPI function, CHO (Chinese-hamster ovary) cells, which produce abundant caveolin-1 [18] , were transfected with TF, and then co-transfected with TFPI chimaeras that attach TFPI to the cell surface either through a GPI anchor (TFPI-GPI) or a transmembrane anchor (TFPI-TM). Cellular clones expressing equal amounts of TF and TFPI chimaera were characterized for TFPI membrane localization and studied in fXa-and TF-fVIIainitiated assay systems. The results demonstrate that localization of TFPI within caveolae does not affect the inhibition of fXa activity, but substantially increases inhibition of TF-fVIIa.
EXPERIMENTAL

Cell culture
CHO cells (CHO-K1) (A.T.C.C., Manassas, VA, U.S.A.) were cultured in F12 medium (Mediatech). HUVECs (human umbilical vein endothelial cells) (Core Facility, Blood Center of Wisconsin) and the EA.hy926 endothelial cell line (A.T.C.C.) were grown in MCDB-131 medium. All media were supplemented with 10 % fetal bovine serum (BioWest), and endothelial cell medium contained 1 % penicillin/streptomycin (Mediatech) before use.
CHO cell transfections
Constructs encoding the TFPI chimaeras TFPI-GPI or TFPI-TM, which contain amino acids 1-252 of human TFPIα followed by either a GPI anchor target sequence from decay-accelerating factor (TFPI-GPI) or a hydrophobic stretch of amino acids making up a transmembrane attachment from HLA-B44 (TFPI-TM), were as described previously [17] . The full-length TF construct was a gift from Dr Wolfram Ruf (The Scripps Research Institute, La Jolla, CA, U.S.A.). The region encoding TFPIβ was amplified from human cDNA by PCR and ligated into the pDisplay plasmid (Invitrogen). CHO cells were transfected with the TF construct using Lipofectamine TM (Invitrogen) according to the manufacturer's instructions. Stable CHO-TF clones were produced using hygromycin and two rounds of cloning. They were screened by flow cytometry, and a clone expressing high amounts of TF was chosen to co-transfect with the TFPI-GPI, TFPI-TM or TFPIβ construct. Stable CHO-TF/TFPI-GPI, CHO-TF/TFPI-TM and CHO-TF/TFPIβ co-transfectants were selected using a combination of hygromycin and G-418. Cells were cloned and screened by flow cytometry to select clones expressing approximately equal amounts of TFPI-GPI, TFPI-TM or TFPIβ.
Standardization of cellular preparations
The concentrations of the different cellular clones used for most experiments were standardized through measurement of total protein [BCA (bincinchoninic acid) Protein Assay kit, Pierce]. This was found to be a more accurate means for standardizing cell concentration than counting using a haemocytometer. Briefly, cells were seeded on to 100-mm-diameter tissue culture plates and grown to 90 % confluence. They were washed with PBS and harvested with 10 mM EDTA in PBS containing protease inhibitors (50 μM 3,4-dichloroisocoumarin; 100 μM E-64, Sigma) using a cell scraper. Cells were washed after centrifugation at 182 g for 15 min, then resuspended in 1 ml of PBS. A 100 μl aliquot was pelleted by centrifugation and lysed in cell lysis buffer (30 mM CHAPS and 10 mM EDTA in PBS, pH 7.0) before assay. The remainder of the cell suspension was kept on ice for approximately 2 h before assay to allow the protease inhibitors to hydrolyse.
PI-PLC (phosphatidylinositol-specific phospholipase C) cell treatment
Cells were harvested as described above then resuspended in PBS containing 1 unit/ml PI-PLC (Invitrogen) and incubated for 1 h at 37
• C. Cells were centrifuged at 1200 g for 10 min and collected for flow cytometric analysis.
M-β-CD cell treatment
Cells were grown to 90 % confluence, harvested, resuspended in the appropriate basal medium without additives and incubated with 10 mM α-CD (α-cyclodextrin) or M-β-CD for 30 min at 37
• C. They were centrifuged at 1200 g for 10 min, washed with 1 ml of PBS, and resuspended in HBSA (Hepes-buffered saline albumin: 50 mM Hepes, 100 mM NaCl, 10 mM CaCl 2 and 0.1 % BSA, pH 7.4) before assay.
LPS (lipopolysaccharide) cell treatment
EA.hy926 cells and HUVECs were treated with LPS to induce TF expression before determination of their potential to generate fXa in a TF-fVIIa-dependent manner. Briefly, cells were grown to 80-90 % confluence, washed with PBS and incubated with 1 μg/ml LPS in the appropriate growth medium for 6 h at 37
• C. Cells were harvested and prepared for assay as described above.
Flow cytometry
Cells were harvested, standardized by cell counting, fixed with 1.5 % (w/v) formaldehyde in PBS for 30 min and incubated with primary antibody for 1 h, followed by secondary antibody for 30 min, with washes performed in between. The primary antibodies (10 μg/ml) used were mouse anti-(human TFPI) 2H8 antibody (a gift from Dr George Broze, Washington University, St. Louis, MO, U.S.A.), mouse anti-(human TF) (American Diagnostica) and mouse monoclonal isotype control antibody MOPC-21 (Sigma). Alexa Fluor ® 488-conjugated (Fab ) 2 goat anti-(mouse IgG) (1:500 dilution; Invitrogen) was used as the secondary antibody. Cells were analysed using a BD TM LSRII Flow Cytometer and BD TM FACS Diva Software (BD Bioscience).
Triton X-114 phase separation and Western blotting
Cells were harvested and lysed with 1 ml of Triton X-114 lysis buffer [10 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA and 1 % (v/v) Triton X-114, pH 7.4] for 1 h at 4
• C. The sample was centrifuged at 20 000 g for 10 min at 4
• C and the pellet was saved for further analysis. The supernatant was collected, normalized to approximately 500 μg/ml total protein and layered on to a sucrose cushion (6 % sucrose and 0.06 % Triton X-114 in PBS). It was incubated at 37 • C for 3 min then centrifuged at 400 g for 5 min at 30
• C, separating the sample into an upper aqueous phase and a lower detergent phase. The aqueous phase was collected for further analysis. The detergent phase was resuspended in 500 μl of PBS and phase separation was repeated. The detergentrich phase was resuspended in 1 ml of ice-cold PBS and saved for further analysis. The aqueous phases were pooled, 50 μl of 11.4 % Triton X-114 was added, and phase separation was performed. The aqueous phase was saved for further analysis, and the detergent pellet was discarded. TFPI was isolated from all of the saved fractions by ligand-precipitation using fXa-coupled agarose beads, and was subjected to SDS/PAGE (10 % gels) and Western blot analysis for TFPI as described previously [19] .
I-fVIIa cell-surface-binding assay
Recombinant human fVIIa (Novo Nordisk) was labelled with 125 I to a specific activity of 6 × 10 7 c.p.m./nmol of fVIIa using IodoGen (Pierce) according to the manufacturer's instructions. Cells were seeded after being normalized by total protein measurement and allowed to attach to the well of a 24-well plate overnight. They were washed with ice-cold HBSA containing 11 mM glucose and 5 mM CaCl 2 and incubated with 125 I-fVIIa for 4 h at 4
• C. Cells were washed four times, and bound 125 IfVIIa was removed with 0.1 M glycine (pH 2.5) and quantified using a γ -counter (Packard Cobra Auto-Gamma, PerkinElmer). Cells were incubated in the presence or absence of a 100-fold molar excess of unlabelled fVIIa to determine binding specificity.
fXa-inhibition assay
Cells were harvested, washed with PBS and resuspended in HBSA containing 5 mM CaCl 2 (HBSA/Ca 2 + ). Reaction conditions were prepared containing cells (various concentrations, normalized to total protein) and fXa chromogenic substrate (0.5 mM; Spectrozyme Xa, American Diagnostica) in HBSA/Ca 2 + . Reactions were initiated by addition of fXa (0.1 nM), and substrate cleavage was monitored at 405 nm for 45 min. Initial and final velocities were calculated from the progress curves between 0 and 5 min and between 40 and 45 min respectively, and a fXa standard curve was used to determine the amount of free fXa.
TF-fVIIa-dependent fXa-generation assay
Cells were harvested and mixed with fVIIa (0.02 nM for the TFPI inhibition assay in Figure 1E and 0.01 nM in all other Figures) and fXa chromogenic substrate (500 μM). fX (Factor X) (20 nM) (all final concentrations) was added and substrate cleavage was monitored at 405 nm for 1 h. The maximal rate of substrate cleavage, calculated by SoftMAX Pro software, version 4.3.1 (Molecular Devices), was compared with a standard curve generated using known amounts of fXa (2.5-51.6 nM) to calculate the maximal amount of fXa generated. Some experiments were performed following 30 min of incubation of the CHO cell clones with a monoclonal anti-TFPI antibody (100 μg/ml) directed against the second Kunitz domain (Novo Nordisk).
Plasma-clotting assay
Plasma-clotting assays were performed using human microparticle-poor plasma produced by centrifugation of platelet-poor plasma at 60 900 rev./min for 1 h using a Beckman TLA 100.3 rotor. Cells were harvested and normalized to total protein. Cells, diluted in HBSA containing 38 mM CaCl 2 , were added to a cuvette and the reaction was started with 100 μl of plasma. The time to clot formation was determined using a STAT 4 coagulation analyser (Diagnostica Stago).
Statistical analysis
To test for statistical significance, Student's t test or oneway ANOVA were performed using GraphPad Prism for Windows, version 4.0. Bonferroni's Multiple Comparison test was performed to test for differences between groups when the one-way ANOVA was significant. A P value less than 0.05 was considered statistically significant.
RESULTS
Characterization of transfected CHO cells
In order to study the role of caveolae in the inhibition of TF activity by TFPI, CHO cells, known to express caveolin-1 and contain caveolae [18] , were first stably transfected with TF and then stably co-transfected with either the TFPI-GPI or the TFPI-TM chimaera. Flow cytometric analyses demonstrated that TF antigen expression was approximately equal on the selected clones ( Figure 1A ). Binding studies using 125 I-labelled fVIIa were also used to quantify TF on individual clones ( Figure 1B) . The three CHO cell lines transfected with TF bound nearly identical amounts of fVIIa, confirming that co-transfection of the cells with the TFPI chimaera did not alter TF expression. Non-transfected wild-type CHO cells did not bind fVIIa, confirming that the [17] . The lower band in lane B is a possible degradation product, whereas the upper band in lane D may be dimerization of the chimaera [17] or a non-specific product. Molecular masses are indicated on the left in kDa.
observed binding was TF-dependent ( Figure 1B) . Similarly, the three cell lines generated similar amounts of fXa in a TFdependent fXa-generation assay when pre-treated with saturating amounts of anti-TFPI antibody ( Figure 1C ), confirming that they express essentially equal amounts of functional TF.
Flow cytometry for TFPI demonstrated similar amounts of TFPI antigen on the clones expressing TFPI ( Figure 1D ). Consistent with this finding, these clones exhibited similar total cell-surface fXa-inhibitory capacity ( Figure 1E) . A small fraction of the CHO cell clone expressing only TF also reacted with the anti-TFPI antibody ( Figure 1D) . However, the absence of fXa-inhibitory activity on these cells suggests that this is a non-specific reaction rather than endogenous CHO cell TFPI.
TFPI-GPI and TFPI-TM localize within different lipid environments
GPI-anchored proteins can be released from the cell surface by PI-PLC, which cleaves the phosphoglycerol bond within the GPI anchor [20] . The clones transfected with the TFPI chimaeras were treated with PI-PLC, and removal of cell-surface TFPI was assessed by flow cytometry. PI-PLC reduced TFPI antigen on the surface of cells transfected with TFPI-GPI by 93 % (Figure 2A) , confirming that TFPI-GPI is GPI-anchored [17, 21] . In contrast, PI-PLC reduced TFPI antigen on the surface of cells transfected with TFPI-TM by only 13 %, an amount consistent with that removed during control reactions with PBS ( Figure 2A , and results not shown), confirming that it is transmembrane-anchored [17] . Cellular lysis with TX-114 at 4
• C was used to assess the lipid environment of TFPI-GPI and TFPI-TM. This separates cellular proteins into three phases: a detergent-insoluble highly phospholipid-rich fraction which contains lipid rafts and associated proteins that precipitate at 4
• C, and, after warming to 30
• C, a detergent phase which contains phospholipid and membrane proteins, and an aqueous phase which contains soluble proteins and some membrane proteins [22] . Western blot analysis revealed differential localization of the TFPI chimaeras ( Figure 2B ). The majority of TFPI-GPI was consistently present in the lipid raft pellet ( Figure 2B , lane G), with the remainder in the detergent phase ( Figure 2B, lane F) . In contrast, TFPI-TM was found predominantly in the aqueous phase ( Figure 2B , lane B). These results are again consistent with the localization of TFPI-GPI to lipid rafts [17, 21] and TFPI-TM to the bulk plasma membrane [17] . There was variability in Western blot band intensity between the TFPI-GPI and TFPI-TM cells despite normalizing for total cellular protein before lysis with TX-114. This was not cell-line-specific, as noted in repeated runs of this assay. Therefore the differences in band intensity observed are likely to be due to variable protein loss during the fractionation procedure.
Inhibition of fXa by TFPI is not dependent on localization within caveolae
To assess whether the localization of TFPI to caveolae contributes to its fXa-inhibitory activity, CHO cells, expressing either TFPI-TM or TFPI-GPI, were incubated with fXa and cleavage of fXa chromogenic substrate was monitored over time. Nearly identical progress curves were obtained with the two TFPI constructs, demonstrating that localization of TFPI within caveolae does not alter the rate of fXa inhibition (Figure 3 ). The initial (from 0 to 5 min) and final (from 40 to 45 min) reaction velocities were used to calculate the amount of uninhibited fXa at the initial stages of the reaction and at steady-state respectively (Table 1) . Statistical analysis of these data demonstrated that there was no difference between TFPI-GPI and TFPI-TM (P > 0.05), confirming that the localization of TFPI to caveolae does not affect its direct fXa-inhibitory activity.
Table 1 Localization of TFPI to caveolae does not affect its fXa-inhibitory activity
The fXa-inhibitory assay was performed on CHO-TF, CHO-TF/TFPI-TM and CHO-TF/TFPI-GPI cells in suspension at equivalent concentrations (300 μg/ml total cellular protein). 
Inhibition of TF-fVIIa-mediated generation of fXa by TFPI is enhanced by caveolae
To determine whether the TF-fVIIa-inhibitory activity of cellsurface TFPI is altered by localization to caveolae, the CHO cell clones were incubated with fVIIa and fX, and the generation of fXa was monitored over time ( Figure 4A ). Since these clones expressed greater amounts of TF than TFPI, fVIIa was used as the limiting reagent in these assays. The CHO cells expressing only TF generated a maximum fXa concentration of 45.3 + − 1.0 nM. This was reduced approximately 18 % in cells expressing TFPI-TM to 37.3 + − 1.0 nM (P < 0.001 compared with CHO-TF cells) and by 37 % in cells expressing TFPI-GPI to 28.4 + − 1.3 nM (P < 0.001 compared with CHO-TF cells). The maximum amount of fXa generated was reduced by 24 % on the surface of cells expressing TFPI-GPI compared with those expressing TFPI-TM (P < 0.001) ( Figure 4B ).
Membrane cholesterol depletion reduces TFPI-GPI-inhibitory activity to that of TFPI-TM
To investigate further the effect of TFPI localization to caveolae, fXa-generation assays were repeated using CHO cell clones that had been treated with M-β-CD to remove cholesterol from the cell membrane. Treatment of the cells with α-CD, which does not remove membrane cholesterol, served as a comparative control. Previous studies have demonstrated that M-β-CD can increase [23] or decrease [24, 25] functional TF at the cell surface, depending on the cell type. Therefore cyclodextrin treatment was first performed on CHO-TF cells to determine its effect on TF activity in this cell line. The maximum concentration of fXa generated was minimally decreased by α-CD compared with both M-β-CD and a PBS control (38.1 + − 0.5 compared with 40.5 + − 0.5 and 41.0 + − 0.8 nM respectively, P < 0.05; Figure 5A ). The minor effect observed with α-CD may be due to perturbation of the bulk plasma membrane [26] . However, given that there was no difference in fXa generation between M-β-CD-treated and PBStreated cells, it can be concluded that M-β-CD does not increase TF activity on the CHO cell surface. M-β-CD treatment did not alter the amount of fXa generated for cells expressing TFPI-TM (M-β-CD: 30.2 + − 2.2 compared with α-CD: 30.6 + − 2.6 nM, P > 0.05; Figure 5B ), a finding that is again consistent with the localization of TFPI-TM within the bulk membrane. In contrast, M-β-CD treatment of CHO-TF cells expressing TFPI-GPI significantly increased the amount of fXa (27.4 + − 0.7 nM for M-β-CD compared with 17.1 + − 1.3 nM for α-CD, P < 0.001; Figure 5B ) almost to that observed for cells expressing TFPI-TM. It is noted that M-β-CD treatment may selectively release GPI-anchored proteins from the cell membrane [27] , as has been observed previously with TFPI-GPI expressed in HEK-293 cells [17] . No such release was observed with CHO-TF cells expressing TFPI-GPI, as assessed by flow cytometry after α-CD and M-β-CD treatment (results not shown), and therefore the increased fXa generation demonstrated with TFPI-GPI cells after M-β-CD treatment is not due to loss of the inhibitor from the cell surface.
Inhibition of TF-fVIIa-initiated plasma clotting by TFPI is enhanced by caveolae
TF-initiated plasma-clotting assays were used to assess further the role of caveolae in TFPI anticoagulant activity. Cells expressing TFPI-TM increased the time to clot formation by 29 % compared 
Caveolae enhance inhibition of TF-fVIIa, but not fXa, by the natural TFPI isoforms
The TFPI-GPI and TFPI-TM chimaeras are altered forms of TFPIα. Endogenous TFPI is an alternatively spliced protein with two major isoforms produced in humans, TFPIα and TFPIβ [5] . To investigate how caveolae alter the inhibitory activity of these isoforms, M-β-CD was used to deplete the membrane cholesterol of EA.hy926 cells, demonstrated previously to express TFPIα [19] , and CHO-TF cells transfected with TFPIβ. In addition, HUVECs were examined as a primary cell line that expresses TFPI, although the TFPI isoform expression has not been characterized. Again, treatment of the cells with α-CD served as a comparative control. Consistent with the CHO cell experiments, M-β-CD treatment of these cells did not affect their direct fXa-inhibitory activity (Table 2 ). In contrast, M-β-CD treatment of these cells decreased their TF-fVIIa-inhibitory activity in fXa-generation assays ( Figure 7 ). The greatest effect was observed with EA.hy926 cells, where M-β-CD resulted in a 67 % increase in the amount of fXa generated (44.1 + − 5.5 nM for M-β-CD compared with 26.5 + − 4.2 nM for α-CD, P < 0.001).
The maximum amount of fXa generated was also significantly increased by M-β-CD treatment of HUVECs (41 % increase: 39.6 + − 2.9 for M-β-CD compared with 27.9 + − 1.5 nM for α-CD, P < 0.01) and CHO-Hβ cells (18 % increase: 32.1 + − 1.6 nM for M-β-CD compared with 27.1 + − 1.3 nM for α-CD, P < 0.001).
DISCUSSION
TFPI is a GPI-anchored protein that localizes within caveolae on the endothelial surface [7, 8, 11] . The presence of caveolae on the cell surface enhances TFPI anticoagulant activity and redistributes TF-fVIIa to detergent-insoluble microdomains that contain lipids, which only weakly support procoagulant proteolytic reactions [8] . In the present study, we have produced CHO cell lines that express TF and either TFPI-GPI or TFPI-TM to further define and quantify the enhancing effect of caveolae on TFPI anticoagulant activity. Studies with these cells demonstrate that localization of TFPI to caveolae enhances the inhibition of TFfVIIa-dependent fXa generation by approximately 30 %, but has no effect on fXa-inhibitory activity. This effect was also present, and perhaps more substantial, in plasma-clotting assays, where TFPI localized to caveolae increased the time to clot formation by 65 % compared with TFPI localized to the bulk membrane. Since the chimaeras expressed in the CHO cells are altered forms of TFPI, cell lines expressing TFPIα and/or TFPIβ were also studied to determine whether caveolae enhance the anticoagulant activity of endogenous TFPI isoforms. In EA.hy926 cells, HUVECs and CHO cells transfected with TFPIβ, caveolae enhanced TFPI TF-fVIIa-inhibitory activity, but had no effect on fXa-inhibitory activity, demonstrating that localization to caveolae enhances the anticoagulant activity of endogenously produced TFPI.
The second Kunitz domain of TFPI is a potent direct inhibitor of fXa [1] . The rate of inhibition is readily altered in solutionphase assays by proteins or chemicals that interact with the third Kunitz domain or basic C-terminal region of TFPIα, including Factor V, Ca 2 + , heparin [28, 29] and Protein S [30, 31] . For example, Ca 2 + ions substantially decrease the K i (initial) and K i (final) for inhibition of fXa by blocking interactions between the C-terminus of TFPIα and the Gla domain of fXa [28, 29] . This decrease is abrogated when phospholipid and Factor Va or heparin are included in the assay system [28, 29] . In contrast with the variability in the rate of fXa inhibition observed in solution-phase assays, the inhibition of fXa was not affected by the lipid environment of any cell-surface-associated form of TFPI examined in the present paper. Thus the surrounding lipid composition of cell-surface-bound TFPI, and specifically its localization within caveolae, does not alter the accessibility of the second Kunitz domain to the active site of fXa.
Although the second Kunitz domain of TFPI inhibits fXa directly, the first Kunitz domain is an fXa-dependent inhibitor of TF-fVIIa [1] . Although these reactions are often described as being sequential, with TFPI inhibiting fXa and then TFPI-fXa inhibiting TF-fVIIa, kinetic studies indicate that TFPI actually simultaneously inhibits fXa and TF-fVIIa in the ternary TFfVIIa-fXa complex that forms immediately after fX is activated by TF-fVIIa [32] . Neither the C-terminal region of TFPIα [33] nor Protein S [31] , which localizes soluble TFPI to phospholipid surfaces, enhance the inhibitory activity of soluble TFPI in reactions measuring the inhibition of fXa generation by TF-fVIIa. However, TFPI-GPI was a substantially better inhibitor of fXa generation than TFPI-TM, and treatment with the cholesterolsequestering reagent M-β-CD decreased the inhibitory rate of TFPI-GPI to approximately that of TFPI-TM. Similarly, TFPI-GPI was a more potent anticoagulant than TFPI-TM in TFinitiated plasma-clotting assays. Thus localization within caveolae enhances inhibition of TF-fVIIa, but not fXa, by cell-surfaceassociated TFPI.
Studies by Awasthi et al. [24] demonstrated that TF localizes within caveolae on the surface of MDA-MB-231 cells; however, localization within caveolae was not necessary for its procoagulant activity. We have reported that TFPI-GPI and TFPI-TM are equally effective inhibitors of TF-fVIIa-mediated generation of fXa when expressed on the surface of HEK-293 cells [17] . However, HEK-293 cells do not express caveolin-1 and do not have caveolae [34, 35] . It therefore appears that lipid rafts alone do not enhance TFPI activity. Lupu et al. [16] demonstrated that caveolin-1 transfection into HEK-293 cells results in caveolae formation and decreased lateral mobility of TFPI on the cell surface, perhaps enhancing its ability to interact with TF-fVIIa within caveolae. These investigators demonstrated further that siRNA (small interfering RNA) knockdown of caveolin-1 in HUVECs and EA.hy926 cells decreases cellsurface TFPI expression and activity [16] . The present study investigating TFPI activity on CHO cells suggests that caveolin-1 alone is not sufficient for enhancing TFPI activity, as removal of membrane cholesterol decreased TFPI activity, while maintaining the expression of caveolin-1 at the cell surface [27, 36] . It therefore appears that the formation of caveolae is more important for enhancing TFPI anticoagulant activity than the lipid environment or caveolin-1 alone, so perhaps caveolae localize TF and TFPI in cellular microdomains that allow for optimal recognition of TF-fVIIa by TFPI.
Studies using M-β-CD to disrupt caveolae in EA.hy926 cells, HUVECs and CHO cells expressing TFPIβ were performed to investigate how caveolae alter the activity of TFPIα and TFPIβ. As was observed with the TFPI chimaeras expressed in CHO cells, caveolae enhanced the inhibition of TF-fVIIa, but not fXa, by endogenous TFPI forms produced by the three cell lines. In the cell models used in the present study, caveolae enhanced the inhibitory activity of TFPIα to a greater degree than TFPIβ because the M-β-CD-associated increase in fXa generation in EA.hy926 cells, which produce TFPIα, was greater than that in the CHO cells transfected with TFPIβ (67 % compared with 18 %). However, it is likely that this difference is due to various levels of TF and TFPI expression on the cell surface, resulting in different TF/TFPI ratios, as opposed to caveolae having a lesser effect on the anticoagulant activity of TFPIβ. Since TFPIα and TFPIβ both associate with endothelium through a GPI anchor and localize within caveolae, it is likely that the enhanced inhibition of TF-fVIIa by TFPI within caveolae is a physiologically relevant mechanism to prevent activation of blood coagulation within the vasculature.
AUTHOR CONTRIBUTION
Susan Maroney designed and performed experiments, analysed data and wrote the paper. Paul Ellery designed and performed experiments, analysed data and wrote the paper. Jeremy Wood designed and performed experiments, analysed data and wrote the paper. Josephine Ferrel performed experiments. Catherine Bonesho performed experiments. Alan Mast designed experiments, analysed data and wrote the paper. 
